Virtual Journal Club

Please note: This website is for discussion purposes only. The information provided at this website is not intended to provide treatment advice, or to diagnose or treat any medical disorder. The creator of this website is not responsible for events that occur as a result of decisions made based on the information presented here.

Citations powered by PubMed

Entries Tagged as 'Lancet'

Pulmonary embolism and deep vein thrombosis.

May 23rd, 2012 · Start a Discussion

Pulmonary embolism and deep vein thrombosis.
Lancet. 2012 May 12;379(9828):1835-4…

[Read more →]

Tags: Lancet

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

May 23rd, 2012 · Start a Discussion

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vasc…

[Read more →]

Tags: Lancet

Adult primary central nervous system vasculitis.

May 12th, 2012 · Start a Discussion

Adult primary central nervous system vasculitis.
Lancet. 2012 May 8;
Auth…

[Read more →]

Tags: Lancet

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

April 26th, 2012 · Start a Discussion

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bol…

[Read more →]

Tags: Lancet

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

April 26th, 2012 · Start a Discussion

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bol…

[Read more →]

Tags: Lancet

Cancer of unknown primary site.

March 17th, 2012 · Start a Discussion

Cancer of unknown primary site.
Lancet. 2012 Mar 9;
Authors: Pavlidis N,…

[Read more →]

Tags: Lancet

Burkitt’s lymphoma.

February 16th, 2012 · Start a Discussion

Burkitt’s lymphoma.
Lancet. 2012 Feb 10;
Authors: Molyneux EM, Rochford …

[Read more →]

Tags: Lancet

Lyme borreliosis.

February 15th, 2012 · Start a Discussion

Lyme borreliosis.
Lancet. 2012 Feb 4;379(9814):461-73
Authors: Stanek G,…

[Read more →]

Tags: Lancet

Post-mortem imaging as an alternative to autopsy in the diagnosis of adult deaths: a validation study.

February 9th, 2012 · Start a Discussion

Post-mortem imaging as an alternative to autopsy in the diagnosis of adult deaths: a val…

[Read more →]

Tags: Lancet

Chronic obstructive pulmonary disease.

February 9th, 2012 · Start a Discussion

Chronic obstructive pulmonary disease.
Lancet. 2012 Feb 3;
Authors: Decr…

[Read more →]

Tags: Lancet

Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.

January 19th, 2012 · Start a Discussion

Long-term outcome after additional catheter-directed thrombolysis versus standard treatme…

[Read more →]

Tags: Lancet

Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.

November 29th, 2011 · Start a Discussion

Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up …

[Read more →]

Tags: Lancet

Controversies in treatment of chronic obstructive pulmonary disease.

September 18th, 2011 · Start a Discussion

Controversies in treatment of chronic obstructive pulmonary disease.
Lancet. 2011 Sep 10;378(9795):1038-47
Authors: Rabe KF, Wedzicha JA
Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic disord…

[Read more →]

Tags: Lancet

Thalassaemia.

September 18th, 2011 · Start a Discussion

Thalassaemia.
Lancet. 2011 Sep 9;
Authors: Higgs DR, Engel JD, Stamatoyannopoulos G
Abstract
Thalassaemia is one of the most common genetic diseases worldwide, with at least 60?000 severely affected individua…

[Read more →]

Tags: Lancet

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

August 24th, 2011 · Start a Discussion

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lancet. 2011 Aug 20;378(9792):667-75
Authors: Teerlink JR, Clarke CP, Saikali KG, …

[Read more →]

Tags: Lancet